{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:50:53Z","timestamp":1791881453751,"version":"4.3.4"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:52:58Z","timestamp":1764834778000},"page":"1249-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring reasonable extension of secukinumab dosing intervals in real-world settings"],"prefix":"10.1016","volume":"94","author":[{"given":"Xitong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-0372","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2025.12.007_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jamadermatol.2025.0669","article-title":"Use and cost of first-line biologic medications to treat plaque psoriasis in the US","volume":"161","author":"Rome","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.12.007_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15911","article-title":"Gradually increasing the dosing interval of secukinumab for moderate to severe plaque psoriasis: a single-center, uncontrolled, prospective study in 36 weeks","volume":"35","author":"Chen","year":"2022","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.007_bib3","first-page":"175","article-title":"Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis","volume":"182","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.007_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12248-024-00929-3","article-title":"Impact of obesity on hepatic drug clearance: what are the influential variables?","volume":"26","author":"Zhang","year":"2024","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.007_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2019.01.035","article-title":"Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study","volume":"88","author":"Chiu","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225033171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225033171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:23:42Z","timestamp":1791879822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225033171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225033171"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.007","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring reasonable extension of secukinumab dosing intervals in real-world settings","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}